Drugs Made In America Acquisition II Corp. (DMII)
Drugs Made In America Acquisition II will go public soon, but the exact IPO date is still unknown.
IPO Price
$10.00
Shares Offered
50,000,000
Deal Size
$500.00M
Company Description
Drugs Made In America Acquisition II is a blank check company newly incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
We intend to focus our search for business combination targets in the pharmaceutical industry.
Drugs Made In America Acquisition II Corp.
| Country | United States |
| Founded | 2024 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Lynn Stockwell |
Contact Details
Address: 1 East Broward Boulevard, Suite 700 Fort Lauderdale, FL 33301 United States | |
| Phone | (954) 870-3099 |
Stock Details
| Ticker Symbol | DMII |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0002040475 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Lynn Stockwell | Chief Executive Officer and Executive Chair of the Board |
| Glenn Worman | Chief Financial Officer |
| Catherine Do | Director Nominee |
| G. Sridhar Prasad | Director Nominee |
| Myron W. Shulgan | Director Nominee |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 5, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 21, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 25, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 19, 2025 | DRS | [Cover] Draft Registration Statement |